Drew Burch

Vice President, Strategy & Business Development Thermo Fisher Scientific

Mr. Burch leads strategy and business development for Thermo Fisher Scientific’s $5 billion Life Sciences Solutions Group, which includes leading franchises in biosciences, genetic analysis tools, and bioproduction.  In addition to the business development initiatives across LSG, Drew heads Licensing and Commercial Supply, partnering with customers to provide Thermo Fisher’s products, capabilities and intellectual property through commercial use supply arrangements and licenses.

Prior to joining Thermo Fisher Scientific, Drew headed Barclays’ Global Healthcare Mergers and Acquisitions team for ten years, growing it to become a top five advisory practice globally.  He personally led execution teams advising pharmaceutical, biotechnology, tools & diagnostics leaders and their boards on over $175 billion of industry-defining public company sales, acquisitions, divestitures, carve-outs, and hostile defense assignments.  He began his career and spent 12 years at Merrill Lynch, rising from M&A Analyst to Managing Director.  There he focused on healthcare M&A, particularly advising leading managed care and hospital companies on over $50 billion of acquisitions, divestitures, spin-offs, conversions and demutualizations.

Drew received his BA in Economics & Political Science from Yale University, cum laude, and his MBA from the Stanford Graduate School of Business, as an Arjay Miller Scholar.  He served as a Board member of Lutheran Medical Center, a safety net hospital based in Brooklyn, NY, which is now part of NYU Langone Health System.

About Claritas

Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers. By combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries. We are committed to the highest quality and accessibility of information and our interpretive services and unique approach to reporting set the standard for reliably and clearly communicating genetic information.

Now is the time to integrate genomics into clinical practice to inform, guide and improve medical treatment for kids around the world.